Which has higher earnings & valuation, INVA or CBIO?

Innoviva has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $420.69M 3.76 $271.17M $6.01 3.57 Crescent Biopharma $11.88M 37.80 -$153.94M -$10.91 N/A

Does the media favor INVA or CBIO?

In the previous week, Crescent Biopharma had 2 more articles in the media than Innoviva. MarketBeat recorded 4 mentions for Crescent Biopharma and 2 mentions for Innoviva. Innoviva's average media sentiment score of 1.82 beat Crescent Biopharma's score of 0.93 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CBIO or NVAX?

In the previous week, Novavax had 3 more articles in the media than Crescent Biopharma. MarketBeat recorded 7 mentions for Novavax and 4 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.93 beat Novavax's score of 0.93 indicating that Crescent Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CBIO or MNKD?

In the previous week, MannKind had 18 more articles in the media than Crescent Biopharma. MarketBeat recorded 22 mentions for MannKind and 4 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.93 beat MannKind's score of 0.80 indicating that Crescent Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 8 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CBIO or LXRX?

In the previous week, Crescent Biopharma had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 4 mentions for Crescent Biopharma and 3 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.40 beat Crescent Biopharma's score of 0.93 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, CBIO or GERN?

Geron has higher revenue and earnings than Crescent Biopharma. Geron is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Crescent Biopharma $11.88M 37.80 -$153.94M -$10.91 N/A Geron $183.88M 4.95 -$83.50M -$0.11 N/A

Is CBIO or GERN more profitable?

Crescent Biopharma has a net margin of 0.00% compared to Geron's net margin of -35.48%. Geron's return on equity of -23.31% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Crescent Biopharma N/A -103.44% -88.19% Geron -35.48% -23.31% -10.08%

Does the media favor CBIO or GERN?

In the previous week, Crescent Biopharma had 1 more articles in the media than Geron. MarketBeat recorded 4 mentions for Crescent Biopharma and 3 mentions for Geron. Crescent Biopharma's average media sentiment score of 0.93 beat Geron's score of 0.63 indicating that Crescent Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Crescent Biopharma (CBIO) Competitors

$16.30 -0.73 (-4.29%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$16.24 -0.07 (-0.40%)

As of 07/24/2026 07:34 PM Eastern

Compare

CBIO vs. INVA, NVAX, MNKD, LXRX, and GERN

Should you buy Crescent Biopharma stock or one of its competitors? MarketBeat compares Crescent Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Crescent Biopharma include Innoviva (INVA), Novavax (NVAX), MannKind (MNKD), Lexicon Pharmaceuticals (LXRX), and Geron (GERN). These companies are all part of the "biotechnology" industry.

How does Crescent Biopharma compare to Innoviva?

Innoviva (NASDAQ:INVA) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

In the previous week, Crescent Biopharma had 2 more articles in the media than Innoviva. MarketBeat recorded 4 mentions for Crescent Biopharma and 2 mentions for Innoviva. Innoviva's average media sentiment score of 1.82 beat Crescent Biopharma's score of 0.93 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of Innoviva shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 2.0% of Innoviva shares are held by company insiders. Comparatively, 24.8% of Crescent Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Innoviva has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$420.69M	3.76	$271.17M	$6.01	3.57
Crescent Biopharma	$11.88M	37.80	-$153.94M	-$10.91	N/A

Innoviva has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Innoviva has a net margin of 119.89% compared to Crescent Biopharma's net margin of 0.00%. Innoviva's return on equity of 33.33% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Crescent Biopharma	N/A	-103.44%	-88.19%

Innoviva currently has a consensus target price of $36.20, suggesting a potential upside of 68.84%. Crescent Biopharma has a consensus target price of $29.40, suggesting a potential upside of 80.37%. Given Crescent Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Crescent Biopharma is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Innoviva beats Crescent Biopharma on 10 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to Novavax?

Crescent Biopharma (NASDAQ:CBIO) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Crescent Biopharma has a net margin of 0.00% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-103.44%	-88.19%
Novavax	-14.73%	-14.82%	1.23%

In the previous week, Novavax had 3 more articles in the media than Crescent Biopharma. MarketBeat recorded 7 mentions for Novavax and 4 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.93 beat Novavax's score of 0.93 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by company insiders. Comparatively, 1.6% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Crescent Biopharma has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Novavax has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market.

Crescent Biopharma presently has a consensus price target of $29.40, indicating a potential upside of 80.37%. Novavax has a consensus price target of $13.00, indicating a potential upside of 74.26%. Given Crescent Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Crescent Biopharma is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40

Novavax has higher revenue and earnings than Crescent Biopharma. Novavax is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$11.88M	37.80	-$153.94M	-$10.91	N/A
Novavax	$1.12B	1.09	$440.30M	-$0.58	N/A

Summary

Crescent Biopharma and Novavax tied by winning 8 of the 16 factors compared between the two stocks.

How does Crescent Biopharma compare to MannKind?

Crescent Biopharma (NASDAQ:CBIO) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MannKind has higher revenue and earnings than Crescent Biopharma. MannKind is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$11.88M	37.80	-$153.94M	-$10.91	N/A
MannKind	$348.97M	3.66	$5.86M	-$0.07	N/A

Crescent Biopharma has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, MannKind has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Crescent Biopharma has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-103.44%	-88.19%
MannKind	-6.63%	-11.21%	-3.92%

In the previous week, MannKind had 18 more articles in the media than Crescent Biopharma. MarketBeat recorded 22 mentions for MannKind and 4 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.93 beat MannKind's score of 0.80 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	8 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Crescent Biopharma currently has a consensus target price of $29.40, indicating a potential upside of 80.37%. MannKind has a consensus target price of $8.97, indicating a potential upside of 117.16%. Given MannKind's higher probable upside, analysts plainly believe MannKind is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Crescent Biopharma beats MannKind on 9 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to Lexicon Pharmaceuticals?

Crescent Biopharma (NASDAQ:CBIO) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Crescent Biopharma presently has a consensus price target of $29.40, indicating a potential upside of 80.37%. Lexicon Pharmaceuticals has a consensus price target of $4.55, indicating a potential upside of 98.69%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Lexicon Pharmaceuticals has higher revenue and earnings than Crescent Biopharma. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$11.88M	37.80	-$153.94M	-$10.91	N/A
Lexicon Pharmaceuticals	$49.80M	20.43	-$50.34M	-$0.07	N/A

In the previous week, Crescent Biopharma had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 4 mentions for Crescent Biopharma and 3 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.40 beat Crescent Biopharma's score of 0.93 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Crescent Biopharma has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-103.44%	-88.19%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Crescent Biopharma has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Lexicon Pharmaceuticals beats Crescent Biopharma on 8 of the 15 factors compared between the two stocks.

How does Crescent Biopharma compare to Geron?

Crescent Biopharma (NASDAQ:CBIO) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

In the previous week, Crescent Biopharma had 1 more articles in the media than Geron. MarketBeat recorded 4 mentions for Crescent Biopharma and 3 mentions for Geron. Crescent Biopharma's average media sentiment score of 0.93 beat Geron's score of 0.63 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Crescent Biopharma has a net margin of 0.00% compared to Geron's net margin of -35.48%. Geron's return on equity of -23.31% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-103.44%	-88.19%
Geron	-35.48%	-23.31%	-10.08%

Geron has higher revenue and earnings than Crescent Biopharma. Geron is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$11.88M	37.80	-$153.94M	-$10.91	N/A
Geron	$183.88M	4.95	-$83.50M	-$0.11	N/A

Crescent Biopharma has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, Geron has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

Crescent Biopharma currently has a consensus target price of $29.40, suggesting a potential upside of 80.37%. Geron has a consensus target price of $4.00, suggesting a potential upside of 181.69%. Given Geron's higher possible upside, analysts clearly believe Geron is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

75.2% of Crescent Biopharma shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 24.8% of Crescent Biopharma shares are owned by company insiders. Comparatively, 1.7% of Geron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Crescent Biopharma beats Geron on 10 of the 16 factors compared between the two stocks.

Get Crescent Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBIO vs. The Competition

Export

Metric	Crescent Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$469.30M	$3.08B	$6.88B	$12.26B
Dividend Yield	N/A	2.07%	2.67%	9.79%
P/E Ratio	-1.49	20.29	27.00	23.71
Price / Sales	37.80	353.88	492.77	76.09
Price / Cash	N/A	27.62	50.54	59.64
Price / Book	1.14	4.13	10.28	6.07
Net Income	-$153.94M	$65.94M	$3.60B	$331.84M
7 Day Performance	10.51%	-4.18%	-1.25%	-1.53%
1 Month Performance	-4.06%	-3.76%	-0.35%	-2.46%
1 Year Performance	22.65%	9.93%	18.41%	13.66%

Crescent Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBIO Crescent Biopharma	2.5268 of 5 stars	$16.30 -4.3%	$29.40 +80.4%	+25.2%	$469.30M	$11.88M	N/A	50	News Coverage Upcoming Earnings
INVA Innoviva	3.0681 of 5 stars	$21.58 +1.4%	$36.20 +67.7%	+13.3%	$1.57B	$420.69M	3.59	100	Positive News
NVAX Novavax	2.19 of 5 stars	$8.07 +2.4%	$13.00 +61.1%	-2.4%	$1.30B	$1.12B	N/A	1,990
MNKD MannKind	3.0069 of 5 stars	$4.05 +1.8%	$8.97 +121.5%	+1.2%	$1.23B	$348.97M	N/A	400	Trending News Analyst Forecast
LXRX Lexicon Pharmaceuticals	1.9671 of 5 stars	$2.38 +2.1%	$4.55 +91.2%	+102.7%	$1.03B	$49.80M	N/A	140	News Coverage Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBIO) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Crescent Biopharma (CBIO) Competitors

CBIO vs. INVA, NVAX, MNKD, LXRX, and GERN

How does Crescent Biopharma compare to Innoviva?

Summary

How does Crescent Biopharma compare to Novavax?

Summary

How does Crescent Biopharma compare to MannKind?

Summary

How does Crescent Biopharma compare to Lexicon Pharmaceuticals?

Summary

How does Crescent Biopharma compare to Geron?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Crescent Biopharma (CBIO) Competitors

CBIO vs. INVA, NVAX, MNKD, LXRX, and GERN

How does Crescent Biopharma compare to Innoviva?

Does the media favor INVA or CBIO?

Do insiders & institutionals have more ownership in INVA or CBIO?

Which has higher earnings & valuation, INVA or CBIO?

Which has more risk & volatility, INVA or CBIO?

Is INVA or CBIO more profitable?

Do analysts rate INVA or CBIO?

Summary

How does Crescent Biopharma compare to Novavax?

Is CBIO or NVAX more profitable?

Does the media refer more to CBIO or NVAX?

Do insiders and institutionals believe in CBIO or NVAX?

Which has more risk & volatility, CBIO or NVAX?

Do analysts prefer CBIO or NVAX?

Which has better earnings and valuation, CBIO or NVAX?

Summary

How does Crescent Biopharma compare to MannKind?

Do institutionals & insiders believe in CBIO or MNKD?

Which has higher valuation and earnings, CBIO or MNKD?

Which has more risk and volatility, CBIO or MNKD?

Is CBIO or MNKD more profitable?

Does the media refer more to CBIO or MNKD?

Do analysts prefer CBIO or MNKD?

Summary

How does Crescent Biopharma compare to Lexicon Pharmaceuticals?

Do analysts prefer CBIO or LXRX?

Which has preferable earnings & valuation, CBIO or LXRX?

Does the media refer more to CBIO or LXRX?

Is CBIO or LXRX more profitable?

Which has more volatility and risk, CBIO or LXRX?

Do institutionals and insiders believe in CBIO or LXRX?

Summary

How does Crescent Biopharma compare to Geron?

Does the media favor CBIO or GERN?

Is CBIO or GERN more profitable?

Which has higher earnings and valuation, CBIO or GERN?

Which has more risk & volatility, CBIO or GERN?

Do analysts rate CBIO or GERN?

Do insiders and institutionals have more ownership in CBIO or GERN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools